Ayala Pharmaceuticals, Inc. (ADXS) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Monmouth Junction, NJ, United States. वर्तमान CEO हैं Kenneth A. Berlin.
ADXS के पास है IPO तिथि 2020-05-08, 20 पूर्णकालिक कर्मचारी, पर सूचीबद्ध Other OTC, बाजार पूंजीकरण $25.71M.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
